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HIGHLIGHTS AND eTOC BLURB 
• PARK2 negatively regulates the PI3K/Akt pathway 
• PARK2 depletion promotes PTEN inactivation by S-nitrosylation and 
ubiquitination 
• AMPK activation triggers PTEN S-nitrosylation in the absence of PARK2 
depletion 
• PARK2 and PTEN loss display striking cooperativity to promote tumorigenesis in 
vivo 
 
Gupta et al. reveal an important missing piece in the dynamic signaling and 
metabolic network governing PI3K/Akt activation. PARK2 inactivation connects 
energy and oxidative stress to Akt activation via redox-mediated inactivation of PTEN 
by S-nitrosylation to support cell survival under conditions of energy deprivation. 
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SUMMARY 
PARK2 is a gene implicated in disease states with opposing responses in cell fate 
determination, yet its contribution in pro-survival signaling is largely unknown. Here, 
we show that PARK2 is altered in over a third of all human cancers and its depletion 
results in enhanced PI3K/Akt activation, and increased vulnerability to 
PI3K/Akt/mTOR inhibitors. PARK2 depletion contributes to AMPK-mediated 
activation of eNOS, enhanced levels of reactive oxygen species and a concomitant 
increase in oxidized nitric oxide levels, thereby promoting inhibition of PTEN by S-
nitrosylation and ubiquitination. Notably, AMPK activation alone is sufficient to induce 
PTEN S-nitrosylation in the absence of PARK2 depletion. Park2 and Pten loss also 
display striking cooperativity to promote tumorigenesis in vivo. Together, our findings 
reveal an important missing mechanism that might account for PTEN suppression in 
PARK2-deficient tumors and highlight the importance of PTEN S-nitrosylation in 
supporting cell survival and proliferation under conditions of energy deprivation. 
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INTRODUCTION 
Cell homeostasis is achieved through an orchestrated balance of cell signaling 
interactions that dictate the likelihood of a cell to escape from normal growth 
restraints or be eliminated from the replicative pool, resulting in cell death. Cancer is 
a group of diseases that are due to escape from cell death control, while Parkinson’s 
disease (PD) portrays a disease that results from accelerated cell death. It would 
seem unlikely that these diseases are related, yet there is increasing evidence to 
suggest that a subset of PD susceptibility genes are also associated with cancer 
(Ong et al., 2014).  
PARK2 was originally identified as a gene associated with the pathogenesis of 
familial PD in early-onset autosomal recessive juvenile Parkinsonism (Kitada et al., 
1998). It has been reported to be mutated in as high as 77% of PD patients with an 
age of onset of <20 years, but only in 3% of patients with an age of onset of >30 
years (Lucking et al., 2000). Subsequently, it has been linked with a wide range of 
disorders including leprosy (Mira et al., 2004), autism (Glessner et al., 2009), type 2 
diabetes mellitus (Wongseree et al., 2009), Alzheimer’s disease (Burns et al., 2009), 
cerebellar ataxia (Periquet et al., 2003), resistance to intracellular pathogen 
infections (Manzanillo et al., 2013) and cancer, where it is somatically deleted in a 
wide spectrum of tumor types (Bernardini et al., 2016). PARK2 is a bona fide 
haploinsufficient tumor suppressor, as depletion of a single PARK2 allele significantly 
increases adenoma development and polyp multiplicity in ApcMin/+ mice (Poulogiannis 
et al., 2010). PARK2 loss also renders mice more susceptible to hepatocellular 
(Fujiwara et al., 2008) and γ-irradiation induced carcinomas (Zhang et al., 2011), 
while ectopic PARK2 expression mitigates cell proliferation in colorectal, glioma, 
breast, hepatocellular, and non-small cell lung cancer cells (Lin et al., 2015; Picchio 
et al., 2004; Poulogiannis et al., 2010; Tay et al., 2010; Veeriah et al., 2010; Wang et 
al., 2004; Yeo et al., 2012).  
The PARK2 gene encodes the E3 ubiquitin ligase Parkin, which mediates the 
ubiquitination of a number of substrate proteins, leading to their proteasomal 
degradation (Dawson and Dawson, 2010). Its activities go beyond the degradative 
ubiquitination and it is implicated in the regulation of multiple cellular processes 
including stress response, mitochondrial biogenesis and stability of G1/S cyclins 
(Corti and Brice, 2013; Gong et al., 2014). Although the underlying mechanisms by 
which pathogenic PARK2 mutations contribute to PD are not entirely understood, 
mitochondrial dysfunction is considered to play a central role in stress-induced 
neuronal cell death associated with the pathogenesis of this disorder. Increased 
oxidative and nitrosative stress is a common phenomenon in both PD and cancer, 
hence it is imperative to identify the molecular pathways underlying the functional 
contribution of PARK2 depletion in these processes.  
Compelling evidence shows that cancer cells utilize multiple pathways including the 
phosphatidylinositol 3-kinase/Akt (PI3K/Akt) signaling pathway to enhance their 
survival and prevent apoptosis under metabolic stress conditions (Trachootham et 
al., 2008). Importantly, PARK2 has previously been associated with the activation of 
the Akt pathway (Fallon et al., 2006; Lin et al., 2015; Yeo et al., 2012), however the 
mechanistic evidence behind its functional contribution is unclear. One study showed 
that Parkin interacts with and ubiquitinates Eps15 to delay the internalization and 
degradation of its adaptor protein EGFR, thereby promoting PI3K/Akt signaling 
(Fallon et al., 2006), while a more recent study suggests that Parkin directly interacts 
with and promotes the ubiquitination of EGFR, leading to diminished activation of 
EGF-induced PI3K/Akt signaling (Lin et al., 2015). These data highlight the need for 
further investigation of the molecular events underlying the role of PARK2 depletion 
in PI3K/Akt-mediated cellular survival.  
In this study, we identified PTEN as an important mediator behind the functional 
contribution of PARK2-depletion in the activation of the PI3K/Akt pathway, and 
further characterized its pivotal role in the tumor suppressor function of PARK2 in 
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vitro and in vivo. Additionally, our results reveal an important missing piece in the 
dynamic signaling and metabolic network connecting AMPK with Akt activation in the 
absence of mTORC1-S6K-dependent negative feedback loop mechanisms (Efeyan 
and Sabatini, 2010), demonstrating a compensatory survival mechanism for cancer 
cells under conditions of energy deprivation.  
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RESULTS 
 
PARK2 genomic and gene expression profiling across human cancers 
We examined the degree of PARK2 deletion on the largest up-to-date collection of 
The Cancer Genome Atlas (TCGA) assembling data from 9,863 primary tumors from 
28 different tumor types (Table S1). Focal deletions (dark blue; Figure 1A) of the 
PARK2 gene were most commonly found in colorectal (21%) and ovarian (25%) 
carcinomas, while a strikingly high number of tumors including lung 
adenocarcinomas, melanomas, bladder, ovarian and pancreatic had an overall >40% 
DNA copy number (DCN) loss of the PARK2 gene [both focal deletion (dark blue) 
and as part of whole or part chromosome arm losses (light blue), Figure 1A]. 
Cholangiosarcomas (CHO) showed a staggering 69% (25/36) rate of overall PARK2 
deletions. In parallel, we also examined the degree of PARK2 mRNA decrease 
between cancer and corresponding normal tissues from a total number of 13,481 
specimens, studied in 127 published microarray datasets (Table S2), covering 25 
tumor types. Notably, there are many cancer types including gliomas, cervical, and 
kidney carcinomas with not the highest frequency of overall PARK2 deletion (<40%), 
but with widespread (up to 69%) decrease or loss of its mRNA expression compared 
to their normal counterparts (>1 log2 fold, red or >0.5 log2 fold, red and yellow; 
Figure 1B, S1A). Vice versa there are some tumor types e.g. ovarian cancer, where 
PARK2 deletion is found in >60% of the cases, yet only a small fraction are reported 
to have low PARK2 mRNA expression. This reflects in part the stringent criteria we 
used to report tumor types with >0.5 fold changes in mRNA expression compared to 
their normal counterparts, but also that the majority (>90%) of PARK2 deletions 
across all tumor types are heterozygous, hence are less likely to cause a marked 
reduction in PARK2 mRNA expression.  
As high as 2/3 of glioma tumors have significantly reduced levels of PARK2 mRNA 
expression compared to their corresponding normal (Figure 1B). We plotted the 
distribution of PARK2 expression across different subgroups of gliomas reminiscent 
of distinct neural cell types, to show that PARK2 is significantly downregulated 
irrespectively of the histological origin of this tumor type (Figure S1B). To identify 
relationships between PARK2 DCN and mRNA expression levels, we plotted the 
distribution of its expression across subgroups of glioblastomas (GBMs) with different 
PARK2 DCN. PARK2 mRNA expression is progressively lower across the different 
subgroups of PARK2 ploidy status (Figure 1C). To assess the prognostic 
significance of this gene across different types of genetic alteration, we also 
performed survival analysis between subgroups of patients with GBM divided based 
on different molecular markers of the PARK2 gene. Interestingly, loss of PARK2 at 
the DNA, mRNA and protein levels (Figure 1D) all correlate with significantly poorer 
survival in patients with GBM (Figure 1E). Of note, PARK2 expression is also 
associated with poorer survival in patients with breast and lung adenocarcinomas 
(Figure S1C-D). Collectively, our data demonstrate that PARK2 is altered in over a 
third of all human cancers. Its widespread loss or decrease across many molecular 
biomarker indicators (DNA, mRNA, protein) significantly correlates with poorer 
survival offering great prognostic and predictive value for clinical practice. 
 
PARK2 regulates the activation of the PI3K/Akt pathway  
The PI3K/Akt pathway is the single most frequently altered signaling cascade across 
all the tumor types with recurrent PARK2 deletions and mRNA loss/reduction (Yuan 
and Cantley, 2008). Activation of the PI3K/AKT/mTOR pathway has also been 
associated with significantly poorer survival across many solid tumors (Ocana et al., 
2014). To investigate whether activation of this pathway is inherently associated with 
loss of the PARK2 gene, we stably expressed two independent hairpins targeted 
against PARK2 in HCT116 cells. Cells with PARK2 knockdown exhibited a 
pronounced increase in Akt phosphorylation compared to control GFP knockdown 
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cells (Figure 2A). Staurosporine is a protein kinase inhibitor that can induce 
apoptosis across many different cell types and Akt hyperactivation has been shown 
to attenuate sensitivity to staurosporine-induced cell death (Mookherjee et al., 2007). 
We showed that PARK2 depletion augmented resistance to staurosporine-induced 
cell death (Figure 2B) and this was consistent with significantly lower apoptotic 
response as indicated by Caspase 3/7 activity (Figure 2C).  
Identification of candidate biomarkers that predict responsiveness to specific 
signaling cascade inhibitors is increasingly important in the era of personalized 
medicine. Accordingly, we assessed the role of PARK2 knockdown to the inhibition 
of various signaling nodes across the PI3K/Akt/mTOR and MAPK pathways. PARK2 
depletion renders cells more sensitive to inhibitors of PI3K (BKM120 and BEZ235), 
Akt (MK2206), and mTOR (BEZ235, Rapamycin and Torin), but it decreases the 
effectiveness of MEK inhibitors PD0325901 and GSK1120212 (Figure 2D-E, S2A-
B). Taken together, these data suggest that PARK2 loss contributes in the activation 
of Akt signaling and the dependence of cells on this pathway, suggesting that PARK2 
deficiency could be used as a biomarker of efficacy and favorable clinical response 
to inhibitors of the PI3K/Akt/mTOR pathway. 
 
PARK2 suppresses Akt activation and tumorigenicity in PTEN wild-type, but 
not PTEN mutant cells 
To explore the significance of Akt activation in the molecular mechanisms that 
PARK2 may contribute to tumor suppression, we tested the effect of PARK2 
overexpression in PTEN wild type (WT) (HCT116 PTEN+/+ and H1299) and PTEN 
mutant (PC3 and HCT116 PTEN-/-) cell line models. Ectopic expression of PARK2 
led to inhibition of Akt phosphorylation in HCT116 cells (Figure 3A). Importantly, we 
showed that PARK2 overexpression led to inhibition of Akt activation upon growth 
factor stimulation in PTEN WT H1299 cells (Figure 3B), but not in the PTEN mutant 
PC3 cells (Figure 3C). This reduction in Akt phosphorylation was also apparent 
when we ectopically expressed PARK2 at levels near the endogenous Parkin levels 
expressed in H460 cells, for both the EGFR WT (H1299) and EGFR null (SW620) 
cells (Figure S2C-D). Unlike in parental PTEN+/+ HCT116 cells, overexpression of 
PARK2 did not reduce Akt phosphorylation in isogenic PTEN-/- HCT116 cells (Figure 
S2E), further supporting a role for PTEN in PARK2-mediated regulation of PI3K/Akt 
signaling.  
Akt has been shown to play a central role in promoting growth factor-mediated cell 
proliferation and migration (Manning and Cantley, 2007). Given that PARK2 inhibits 
Akt phosphorylation, we sought to investigate its functional contribution in 
suppressing some of the cellular functions mediated by Akt activation. HCT116 
PTEN+/+ and H1299 cells exhibited a pronounced reduction in both cell proliferation 
(Figure 3D) and cell migration (Figure 3E) upon PARK2 overexpression. However, 
this was not true for the PTEN mutant, PC3 and isogenic PTEN-/- HCT116 cells that 
showed no effect compared to control empty-vector (EV) expressing cells. No effect 
on cell proliferation and migration was also observed when overexpressing the E3-
Ligase dead C431S Parkin mutant in both PTEN WT and mutant cells (Figure S2F-
H).  
To investigate the tumor suppressor effect of PARK2 in vivo, we retro-orbitally 
injected luciferase labeled H1299 cells overexpressing EV or human PARK2. Ectopic 
expression of PARK2 significantly mitigated the formation of lung metastases 
(Figure 3F-I) in NOD/SCID mice. The luciferase activity in cells expressing the 
PARK2 gene was reduced on both week 3 and 4 post-injection (Figure 3F-G), and 
this was consistent with significantly lower number and smaller size of lung 
metastases, as histopathologically evaluated with H&E-stained sections (Figure 3H-
I). These data show that suppression of Akt activation plays a central role in the 
tumor suppressor function of PARK2, and that the mutational status of PTEN 
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determines the functional contribution of PARK2 loss in Akt-mediated cell 
proliferation and migration.  
 
PARK2 depletion suppresses PTEN protein levels and activity 
To further investigate the role of PTEN in PARK2-mediated regulation of the 
PI3K/Akt pathway, we performed PARK2 knockdown analysis in cell lines with 
abundant Parkin, but either WT PTEN present (HCT116 and H460) or absent (PC3 
and U138). In line with our overexpression studies, PARK2 knockdown induced Akt 
phosphorylation in HCT116 and H460 cells, but not in PC3 or U138 cells (Figure 4A, 
S3A-B) or in the isogenic PTEN-null HCT116 (Figure 4B) and MCF10A cells (Figure 
S3C).  Most importantly, PARK2 depletion led to a >30% reduction in PTEN protein 
levels across all PTEN WT cell lines (Figure 4A-B, S3C) and this observation was 
confirmed in CRISPR/Cas9-mediated PARK2 knockout H460 cells (Figure S3D). 
Previous studies with hypomorphic Pten allelic series of mice have shown that even 
subtle reductions in Pten protein levels can have dramatic consequences in cancer 
progression (Trotman et al., 2003). PTEN is regulated in cancer at the transcriptional, 
post-transcriptional and post-translational levels (Song et al., 2012). To further gain 
insight into this regulation by PARK2, we performed qPCR analysis of both PARK2 
and PTEN following lentiviral knockdown of PARK2 and showed that PARK2 
depletion does not affect PTEN mRNA levels (Figure 4C, S3E). Importantly, PARK2 
depletion resulted in a significantly lower PTEN enzymatic activity (Figure 4D, S3F) 
and higher levels of PI(3,4,5)P3 and PI(3,4)P2 in cells (Figure 4E), further supporting 
the functional contribution of PTEN in PARK2-mediated regulation of the PI3K/Akt 
pathway. Moreover, we were struck to observe a reciprocal correlation between 
Parkin and PTEN protein expression across ten breast cancer cell lines that have 
previously been reported to be WT for PTEN (Figure S3G) (Saal et al., 2008).  
In view of our findings, we speculated that suppression of PTEN protein levels by 
PARK2 depletion might be regulated by proteasome-mediated protein degradation. 
Indeed, treatment with proteasome inhibitor MG132 led to an overall increase in 
PTEN protein levels and no significant difference between GFP and PARK2-
knockdown cells (Figure 4F, S3H). Taken together, these results showed that 
PARK2 depletion suppresses PTEN protein levels and activity and raised an 
interesting hypothesis that mechanistically, this could be regulated, at least in part, 
by ubiquitin proteasome-mediated protein degradation. 
 
Increased oxidative and nitrosative stress upon PARK2 depletion 
Recent evidence shows that Parkin loss leads to a marked decrease in mitochondrial 
biogenesis (Stevens et al., 2015). To investigate the role of PARK2 depletion in 
cellular metabolism, we initially measured the effect of knocking down PARK2 
expression on the oxygen consumption rate (OCR) of shGFP- and shPARK2-
expressing cells in the presence or absence of different mitochondrial stress 
inhibitors, using the Seahorse XFe96 Flux Analyser. Notably, PARK2 depletion 
resulted in a marked decrease in basal, maximal, mitochondrial and non-
mitochondrial respiration (Figure 5A-B, S4A-B).  
We next explored the effects of PARK2 depletion on cellular metabolism by 
performing targeted metabolomic analysis. Consistent with lower OCR levels, 
PARK2 knockdown cells showed a significant decrease in ATP levels (Figure 5C) 
and a concomitant activation of AMPK (Figure 5D, Figure S4C), accompanied by 
the inhibition of mTORC1 signaling (Figure S4D-E). PARK2 depletion also caused a 
reduction across many of the cofactors that contribute in nitric oxide (NO) 
biosynthesis, involving the conversion of L-arginine to L-citrulline (Figure 5E-F). 
Importantly, although all the anaplerotic substrates for NO synthesis were detected to 
be lower in the PARK2 knockdown cells, L-citrulline levels were not significantly 
lower. Although other interpretations are possible, these results are consistent with a 
model in which NOS is activated due to loss of PARK2 such that the substrates for 
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NOS are being consumed at a high rate, while the product of NOS L-citrulline is 
maintained at a relatively constant level. Indeed, consistent with this model, we 
measured the NOS activity and oxidized NO (NO2+NO3) levels and found that they 
are significantly higher in PARK2 knockdown cells (Figure 5G-H, S4F). The latter 
also showed an overall increase in NADP/NADPH ratio (Figure 5I), higher ROS 
levels upon menadione treatment (Figure 5J, S4G), and lower reduced/oxidized 
glutathione (GSH/GSSG) levels (Figure 5K, S4H) compared to GFP control 
knockdown cells. Importantly, besides its function as a regulator of cellular redox 
status, GSH has a crucial role in modulating NO reactivity (Aquilano et al., 2014). NO 
as a free radical is a poor oxidant, hence NO-dependent cysteine oxidation primarily 
occurs in the presence of oxygen or high ROS (Broniowska and Hogg, 2012). Of 
note, we showed that GSH-MEE treatment restored the suppression in PTEN protein 
levels observed in PARK2 knockdown cells (Figure 5L, S4I), while BSO treatment 
further enhanced the reduction in PTEN (Figure S4J). In addition, the activity of 
PTEN in PARK2 knockdown cells in the presence of DTT was comparable to the 
shGFP cells without the DTT pre-incubation (Figure S4K), reinforcing the conclusion 
that the inhibition of PTEN is generated by a redox-dependent modification of 
cysteine residues.  
Mitochondrial dysfunction and oxidative stress are well-recognized mechanisms 
leading to the activation of AMPK that can directly phosphorylate endothelial NOS 
(eNOS) to increase its catalytic activity (Schulz et al., 2009). In line with this, we 
showed that PARK2 knockdown (Figure S4L) or allosteric activation of AMPK 
following treatment with the small molecule activator 991 (Figure 5M) led to an 
increase of eNOS phosphorylation and a reduction in PTEN protein levels. Of note, 
this reduction in PTEN protein levels and concomitant increase in Akt activation that 
was observed in 991-treated cells were decreased upon co-treatment with the NO 
scavenger cPTIO (Figure S4M). Collectively, these results demonstrate that PARK2 
depletion leads to mitochondrial dysfunction, high eNOS activity that is mediated, at 
least in part, by AMPK activation and high ROS levels that together coordinate 
efficient NO oxidation.  
 
PARK2 depletion promotes PTEN S-nitrosylation and ubiquitination 
High NO production exerts a pleiotropic range of biological functions that are 
regulated in part, by a post-translational redox-mediated modification known as S-
nitrosylation of protein cysteine residues. PTEN has previously been identified as a 
target of such modification (Kwak et al., 2010; Numajiri et al., 2011) that leads to the 
inhibition of its enzymatic activity and downstream activation of Akt signaling. In view 
of our previous findings, we speculated that PARK2 depletion-mediated activation of 
the Akt pathway might be regulated by PTEN S-nitrosylation. Indeed, PARK2 
depletion resulted in a marked induction of PTEN S-nitrosylation (SNO-PTEN), as 
indicated both by immunoblotting immunoprecipitated PTEN with the anti-S-
nitrosocysteine antibody (Figure 6A, S5B), as well as by measuring the release of 
NO from S-nitrosothiol of recombinant PTEN using the quantitative fluorescent 2,3-
diaminonaphthalene (DAN) assay (Figure 6B, S5C). Interestingly, PTEN S-
nitrosylation has previously shown to promote its ubiquitination (Kwak et al., 2010), 
which could also explain the reduction in total PTEN protein levels and rescue 
following treatment with the proteasome inhibitor MG132 (Figure 4F, S3H). We 
performed in-cell PTEN ubiquitination assay and showed that PARK2 depletion 
resulted in a marked increase in PTEN ubiquitination with or without pre-treatment 
with MG132 for 6 hours (Figure 6C-D, S5D). Consistent with enhanced PTEN 
ubiquitination, we also found an increased abundance of conjugated ubiquitin (ub) on 
PTEN in PARK2 knockdown HCT116 cells expressing HA-Ubiquitin (Figure S5A). 
An increase in phospho-Akt levels was observed in MG132-treated cells even in the 
absence of PARK2 knockdown (Figure 6C), perhaps reflecting the increase in ub 
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conjugates and PTEN ubiquitination (Figure 6D) resulting from proteasome 
inhibition.  
Cysteine (Cys-83) has previously been identified as the critical cysteine thiol group 
within PTEN’s phosphatase domain that is predominantly targeted for S-nitrosylation, 
and in line with this, C83S mutant PTEN is resistant to modification (Numajiri et al., 
2011). Accordingly, we overexpressed WT and C83S mutant PTEN in the presence 
or absence of PARK2 lentiviral shRNA to show that the C83S mutant was completely 
devoid of S-nitrosylation and rescued Akt activation in PARK2 knockdown cells 
(Figure 6E). Importantly, since the activation of eNOS is also regulated by Akt-
dependent phosphorylation (Dimmeler et al., 1999), our observation raised a 
dilemma whether the contribution of PARK2 depletion to PTEN inhibition by S-
nitrosylation is the consequence of Akt activation or is regulated via AMPK-mediated 
activation of eNOS independently of PI3K-Akt. To address this we treated shGFP- 
and shPARK2-expressing HCT116 with the Akt inhibitor MK-2206 to show that 
inhibition of Akt activity does not rescue S-nitrosylation of PTEN (Figure S5E), nor 
the increased NO levels in PARK2 knockdown cells (Figure S5F). On the contrary, 
siRNA-mediated down-regulation of AMPK (AMPK α1 and α2) led to a reduction in 
PTEN S-nitrosylation in PARK2 knockdown cells (Figure 6F), further supporting the 
mechanistic implication of AMPK in PARK2-mediated activation of Akt.  
To determine the importance of AMPK activation to trigger PTEN S-nitrosylation, we 
tested if AMPK activation alone is sufficient to induce this modification in the absence 
of PARK2 depletion. Activation of AMPK following 991 treatment, glucose deprivation 
or oligomycin treatment all led to a marked increase in PTEN S-nitrosylation (Figure 
6G), identifying a functional cross-talk between AMPK and Akt activation.  
To better understand the physiological importance of PTEN S-nitrosylation in the 
proliferation and survival of cells under conditions of metabolic stress, we performed 
clonogenic assays in PTEN null PC3 cells overexpressing EV, WT or SNO-resistant 
(C83S) PTEN in the presence or absence of the glycolysis inhibitor 2-Deoxy-D-
glucose (2-DG). Although no significant difference in colony formation was detected 
in PTEN-WT overexpressing cells with or without 2-DG treatment, there was a 
marked reduction (~30%) in the number of colonies following 2-DG treatment in PC3 
cells with enforced expression of the C83S mutant PTEN (Figure S6A-C). Moreover, 
we compared the half maximal inhibitory concentrations (IC50s) of 2-DG or 
dichloroacetate (DCA) (PDK inhibitor), both of which result in the activation of AMPK 
in response to ATP depletion, to show that PC3 cells expressing the C83S mutant 
exhibited significantly higher sensitivity to treatment with these drugs, not evident in 
PTEN WT-expressing PC3 cells (Figure S6D-E). Last but not least, and consistent 
with the ability of PARK2 knockdown cells to inactivate WT PTEN, we showed that 
shPARK2 cells proliferate significantly faster than shGFP-expressing cells in the 
presence of ectopic co-expression of WT (Figure S6F), but not C83S mutant PTEN 
(Figure S6G). Taken together, these data demonstrate that PARK2 depletion 
contributes to the activation of Akt signaling through promoting S-nitrosylation and 
ubiquitination of the tumor suppressor PTEN. Notably, our data also highlight a 
previously unexplored mechanism contributing to AMPK-mediated activation of 
PI3K/Akt involving the inhibition of PTEN by S-nitrosylation, which appears to be 
critical for the proliferative capacity and survival of PTEN-proficient cancer cells 
under conditions of energy stress.  
 
Park2 deletion dramatically promotes tumorigenesis in Pten heterozygous 
knock-out mice 
Given the functional contribution of PARK2 depletion in PTEN inactivation by S-
nitrosylation, we performed a bioinformatic analysis to report the copy number 
alterations (CNAs) of PARK2 and PTEN across 995 cancer cell lines of the Cancer 
Cell Line Encyclopedia (CCLE) project. We were struck to identify that almost 1/2 cell 
lines with HET deletion in PTEN (n=145/314, 46.2%) also have HET deletion in 
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PARK2, with the coexistence for LOH at both the PTEN and PARK2 loci being far 
more frequent than PTEN (n=79/314, 25.2%) or PARK2 (n=119/344, 34.6%) LOH 
alone (Figure S7A). We extended this bioinformatic analysis summarizing the 
percentage of PARK2 CNAs of primary tumors or cancer cell lines with PTEN LOH 
on 1,953 specimens across 13 different cancer types from the TCGA database to 
show that there is a strong selection for PARK2 LOH, when one copy of the PTEN 
gene is missing (Figure S7B). 
In an effort to study whether Park2 loss further exacerbates Pten-mediated 
tumorigenesis in vivo, mice with a targeted knockout of Park2 exon 3 (Itier et al., 
2003) were crossed with Pten+/- mice (Di Cristofano et al., 1998). The latter are born 
viable and develop prostatic intraepithelial neoplasia (PIN), as well as numerous 
neoplastic lesions in many organs including skin, colon, endometrium, liver, thyroid, 
and thymus (Di Cristofano et al., 1998; Podsypanina et al., 1999). Although, Pten+/-
/Park2+/- and Pten+/-/Park2-/- mice showed a similar spectrum of tumors like the ones 
detected in Pten+/-/Park2+/+ mice, they were significantly more tumor prone and 
exhibited features reminiscent of mice with a hypomorphic and a knockout Pten allele 
(Figure 7A). Park2 loss was associated with an increased incidence of high-grade 
PIN and low-grade prostate adenocarcinoma (Figure 7B, 7D), as well as significantly 
higher numbers of solid thyroid adenocarcinomas (Figure 7C). Most importantly, 
mice bearing Park2 loss developed tumor types including hystiocytic sarcoma, 
multiple myeloma and osteosarcoma in spine (Figure S7C-D) that have not been 
previously described for the Pten+/- mice. On two occasions, mice bearing both Park2 
and Pten loss developed malignant pheochromocytomas and thyroid 
adenocarcinomas that metastasized to the lung (Figure S7C-D). As a result, Pten+/-
/Park2+/- and Pten+/-/Park2-/- mice showed significantly poorer survival compared to 
Pten+/-/Park2+/+ mice (Figure 7E-F), while no difference in relative survival was found 
between Pten+/-/Park2+/- and Pten+/-/Park2-/- mice (Figure S7E).  
To further assess the contribution of the proposed model on the PARK2-mediated 
inactivation of PTEN in vivo, we performed immunohistochemical (IHC) analysis of 
PTEN and phospho-Akt on tumor sections derived from Pten+/- mice bearing WT, 
heterozygous (HET) or homozygous (HOM) deletion in Park2. Consistent with 
reduced PTEN and elevated phospho-Akt expression observed in the immunoblot 
analyses, Pten+/- tumor epithelia bearing one or no copies of Park2, expressed no or 
low PTEN protein levels and showed significantly higher phospho-Akt staining 
compared to lesions in Pten+/-/Park2+/+ mice (Figure S7F-H). Overall, our analysis 
showed that loss of function of Park2 and Pten displayed striking cooperativity to 
promote tumorigenesis and significantly shorten tumor-free survival.  
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DISCUSSION 
 
The PI3K/Akt pathway represents a complex signaling network that integrates 
numerous upstream stimuli to regulate diverse cellular processes, including cell 
growth, proliferation, survival, and migration (Manning and Cantley, 2007). 
Interestingly, the PARK2 gene is associated with the pathogenesis of disease states 
that are characterized by different responses in cell fate determination, therefore 
understanding its functional contribution in the activation of survival pathways is 
clearly of immense clinical benefit.  
In this study, we identify a PTEN-mediated role for PARK2 depletion in the activation 
of the PI3K/Akt pathway. Of note, recent evidence suggested that PARK2 interacts 
with EGFR to promote its ubiquitination, thereby inhibiting Akt activation (Lin et al., 
2015). However the role of EGFR in PARK2-mediated activation of PI3K-Akt 
signaling might be more complex and/or cell-type specific than previously 
appreciated, as ectopic PARK2 expression suppresses Akt activation even in EGFR-
null SW620 cells.  
PTEN is a well-characterized haploinsufficient tumor suppressor (Di Cristofano et al., 
1998), yet emerging evidence suggests that its function goes beyond its tumor 
suppressor role, as a critical regulator of multiple central nervous system functions 
(Ismail et al., 2012). PTEN loss and subsequent activation of the PI3K/Akt signaling 
promotes the activation of mTOR signaling, which is hyperactive in many cancers 
(Carracedo and Pandolfi, 2008).  Notably, inhibition of mTORC1 by rapamycin 
treatment prevents PD symptoms in mice bearing a human mutation in the PARK2 
gene (Siddiqui et al., 2015). Furthermore, PTEN loss leads to downregulation of 
PINK1 expression (Unoki and Nakamura, 2001) supporting a mechanism to suggest 
that PARK2 LOH could repress PINK1 through inactivating PTEN, and PINK1 
repression could obliterate any residual activity of the remaining PARK2 allele, by 
abrogating Parkin translocation to mitochondria.  
An important mode of NO function primarily involves its reaction with oxygen or ROS 
and subsequent oxidation to nitrogen dioxide (NO2), dinitrogen trioxide (N2O3), or 
peroxynitrite (ONOO−), which ultimately lead to nitrosative stress and S-nitrosylation 
of target proteins and other biomolecules (Kovacs and Lindermayr, 2013). Of note, 
NO signaling and S-nitrosylation has previously been detected to contribute to PTEN 
inactivation in neurodegeneration (Kwak et al., 2010), but its role in cancer has been 
largely unknown. In this study, we showed that one of the most common genetic 
alterations across human cancers - PARK2 loss, contributes to S-nitrosylation of 
PTEN, thereby promoting its ubiquitin-dependent degradation by the proteasome. 
We also report that there is a strong selection for co-occurrence of PARK2 and 
PTEN LOH in cancer. This suggests that the high incidence of complete IHC loss of 
PTEN in PTEN HET tumors could be explained, at least in part, due to PARK2 LOH, 
leading to S-nitrosylation and ubiquitination of the protein encoded from the 
remaining PTEN allele. In line with our previous observations (Poulogiannis et al., 
2010), PARK2 has many of the properties of a haploinsufficient tumor suppressor in 
that loss of a single Park2 allele exacerbates tumorigenesis without requiring 
complete inactivation of the remaining allele. 
Notably, activation of AMPK alone can trigger a marked increase in PTEN S-
nitrosylation, pointing to a functional cross-talk between AMPK and Akt activation in 
the absence of any mTORC1-dependent negative feedback loop mechanisms 
(Efeyan and Sabatini, 2010). This redox-dependent modification in PTEN is 
important for supporting the survival and proliferative capacity of energy deprived 
cancer cells, signifying an important compensatory role for AMPK to support cell 
homeostasis via PTEN-mediated activation of Akt signaling. Further studies are 
needed to determine the physiological functions of enhanced NO signaling across 
different disease states, but the reaction between NO and PTEN forms a nexus that 
opens up unique therapeutic opportunities for targeting dysregulated protein S-
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nitrosylation for a substantial fraction of tumors growing under conditions of energy 
deprivation. 
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FIGURE LEGENDS 
 
Figure 1. Genetic landscape of PARK2 copy-number and mRNA expression 
across human cancers.  
(A) Frequencies of PARK2 deletion from 9,863 primary tumors across 28 different 
cancer types. Colored bars describe the percentage of tumor samples showing focal 
deletion; dark blue, overall deletion; light blue, diploid/no focal gain; grey.  
 
(B) Frequencies of relative fold-change of PARK2 mRNA underexpression between 
cancerous and corresponding normal tissues (≥0.5 and ≥1-log2-fold change in tumor 
versus normal). The analysis was performed on 13,481 specimens from 25 different 
cancer types (mRNA downregulated ≥1-log2-fold change; red, mRNA downregulated 
≥0.5-log2-fold; yellow, no loss of mRNA expression; grey). The putative DCN and 
mRNA expression data for PARK2 were retrieved from the TCGA database. 
 
(C) PARK2 mRNA expression in subgroups of primary GBMs of different ploidy 
status, ranging from gain (N=24), to diploid (N=376), heterozygous deletion; Hetloss 
(N=158) and homozygous deletion; Homdel (N=19) (P = 3.5x10-7, one-way Anova 
analysis).  
 
(D) Representative IHC staining intensities of PARKIN protein expression across 61 
GBM specimens.  
 
(E) Kaplan-meier survival plots of glioma cancer patients stratified by tumors bearing 
PARK2 deletion versus retention [left; PARK2 Deleted: ≤ 1.8 copies (n=24), PARK2 
Diploid: = 2 copies, (n=149)], low versus intermediate PARK2 mRNA expression 
[middle; PARK2 Low: ≥ 2x lower than log2 median expression (n=92), PARK2 
Intermediate: < 2x lower or higher than log2 median expression (n=251)], and 
positive versus negative IHC PARKIN protein expression (right) (from left to right: P = 
0.032, P = 4x10-4, P = 0.01, Log-rank test).  
 
See also Figure S1 and Tables S1-2. 
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Figure 2. PARK2 depletion contributes to the activation of the PI3K/Akt 
pathway. 
(A) Immunoblotting analysis of HCT116 cells stably transfected with control GFP 
(shGFP) or PARK2 (shPARK2_1 and shPARK2_2) lentiviral hairpins.  
 
(B) MTS assay and (C) Caspase 3/7 activity assay of shGFP or shPARK2 HCT116 
cells, following treatment with increasing concentrations of staurosporine (50nM and 
100nM) for 1 hour (MTS assay; P = 0.001 for 50nM, and P = 0.0008 for 100nM 
treatment, caspase 3/7 assay; P = 0.043 for 50nM, P = 0.036 for 100nM treatment).  
 
(D) Immunoblotting analysis of shGFP and shPARK2 HCT116 cells following 
treatment with the indicated compounds; 1 µM BKM (NVP-BKM120) or 500 nM BEZ 
(NVP-BEZ235) for 24 hours, 500 nM MK (MK 2206) for 4 hours, 100nM Rapa 
(Rapamycin) or Torin for 2 hours, 100 nM PD0 (PD0325901) for 1 hour or 10 nM 
GSK (GSK1120212) for 6 hours.  
 
(E) Drug dose-response curves of shGFP and shPARK2 HCT116 cells treated with 
the indicated compounds for 24 hours (NVP-BKM120; P = 0.014, NVP-BEZ235; P = 
9.28 x10-5, MK 2206; P = 1 x10-4, Rapamycin; P = 1.45 x10-11, Torin; P = 6.73 x10-10, 
PD0325901; P = 0.02, GSK1120212; P = 0.03, two-way Anova analysis). Data are 
represented as mean ±SEM (*P<0.05, **P<0.01, 2-tailed t test).  
 
See also Figure S2. 
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Figure 3. PARK2 overexpression suppresses Akt activation, and mitigates cell 
proliferation and migration in PTEN wild-type, but not PTEN mutant cells. 
Immunoblotting analysis of 
(A) HCT116 cells transfected with vector only or vector encoding WT PARK2.  
 
(B) PTEN WT H1299 cells and 
 
(C) PTEN mutant PC3 cells expressing vector only or vector encoding WT PARK2 
following 10% FBS stimulation. Cells were serum-starved for 24 hours prior to FBS 
stimulation. 
 
(D) Cell proliferation (HCT116 PTEN+/+; P = 0.002, HCT116 PTEN-/-; P = 0.99, 
H1299; P = 3.4x10-5, PC3; P = 0.66, two-way Anova analysis) and  
 
(E) Cell migration assays of PTEN-WT (HCT116 PTEN+/+ and H1299) and PTEN-
deficient (HCT116 PTEN-/- and PC3) cells expressing vector only or vector encoding 
WT PARK2 (HCT116 PTEN+/+; P = 8.1x10-4, HCT116 PTEN-/-; P = 0.99, H1299; P = 
4.7x10-3, PC3; P = 0.68).  
 
(F) BLI images of NOD/SCID mice retro-orbitally injected with luciferase labelled 
H1299 cells expressing EV or human PARK2. Images were taken at 3 and 4 weeks 
post-injection (W3 and W4) to assess for luciferase-expressing lung metastases.  
 
(G) Quantification of BLI intensities on week 3 and 4 post-injection (EV; P = 0.02 and 
human PARK2; P = 0.54). The lungs were then dissected from the mice for H&E 
staining.  
 
(H) Scatterplot indicating that overexpression of PARK2 significantly mitigated the 
formation of lung metastases in NOD/SCID mice (P = 0.006).  
 
(I) Representative H&E staining of lung sections 4 weeks post-injection to highlight 
significantly more and larger size metastatic tumor lesions in the mice injected with 
vector only or with vector encoding WT PARK2 H1299 cells. Data are represented as 
mean ±SEM (n.s.: not significant, *P<0.05, **P<0.01, 2-tailed t test).  
 
See also Figure S2. 
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Figure 4. PARK2 depletion contributes to Akt activation in a PTEN-dependent 
manner. 
(A-B) Immunoblotting of shGFP and shPARK2 PTEN WT HCT116parental, H460 and 
HCT116PTEN+/+ or PTEN mutant PC3, U138 and HCT116PTEN-/- cells. 
  
(C) Quantitative real-time PCR for PARK2 and PTEN on mRNA isolated from shGFP 
and shPARK2 HCT116 cells (PARK2 qPCR; P = 0.001, PTEN qPCR; P = 0.44).  
 
(D) PTEN activity assay (P = 0.015), and  
 
(E) Phosphoinositide PI(3,4,5)P3 and PI(3,4)P2 levels between shGFP and shPARK2 
HCT116 cells [PI(3,4,5)P3; P = 0.002, PI(3,4)P2; P = 0.015]. PTEN was ectopically 
expressed equally between cells. 
 
(F) Immunoblotting of shGFP and shPARK2 HCT116 cells with or without treatment 
with 10 µM MG132 for 6 hours. Data are represented as mean ±SEM (n.s.: not 
significant, *P<0.05, **P<0.01, 2-tailed t test).  
 
See also Figures S3 and S4. 
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Figure 5. The role of PARK2 depletion in cellular metabolism and AMPK-
mediated eNOS activation.  
(A) Seahorse analysis of OCR following sequential injection of oligomycin, FCCP and 
antimycin A/rotenone (n=6), 
 
(B) OCR of basal (P = 0.016), maximal (P = 0.003) and non-mitochondrial respiration 
(P = 0.037), 
 
(C) Relative ATP levels (P = 0.02), and 
 
(D) Immunoblotting analysis between shGFP and shPARK2 HCT116 cells. 
 
(E) Schematic representation of NO biosynthesis involving the conversion of L-
arginine into L-citrulline by NOS in the presence of cofactors including NADPH, FAD, 
FMN, CaM, O2 and BH4.  
 
(F) Relative abundance of metabolites involved in NO biosynthesis following PARK2 
knockdown in HCT116 cells (FAD; P = 0.002, FMN; P = 0.011, NADP; P = 0.025, 
NADPH; P = 0.019, Arginine; P = 0.063, Citrulline, P = 0.24). 
 
(G) Relative NOS activity (P = 0.017),  
 
(H) Oxidised NO levels (P = 5.1x10-4), 
 
(I) NADP/NADPH levels (P = 0.013),  
 
(J) ROS levels following 2 hours menadione treatment (20uM) (P = 0.006),  
 
(K) GSH/GSSG levels between shGFP and shPARK2 HCT116 cells (P = 0.008). 
 
Immunoblotting analysis of 
(L) shGFP and shPARK2 HCT116 cells with or without treatment with 5mM GSH-
MEE for 72 hours.  
 
(M) HCT116 cells following treatment with the indicated concentrations (0-20 µM) of 
the allosteric AMPK activator 991 for 5 hours. Cells were serum-starved for 2 hours 
prior to 991 treatment. Data are represented as mean ±SEM (n.s.: not significant, 
*P<0.05, **P<0.01, 2-tailed t test).  
 
See also Figure S4. 
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Figure 6. PARK2 depletion leads to enhanced S-nitrosylation and 
ubiquitination of PTEN. 
(A) Anti-PTEN immunoprecipitates (IP) derived from MYC-tagged transfected PTEN 
HCT116 cells expressing GFP or PARK2 shRNA.  
 
(B) Fluorometric measurement of S-nitrosylated PTEN between shGFP and 
shPARK2 HCT116 cells. SNO-PTEN was assessed by NO release, causing the 
conversion of DAN to the fluorescent compound NAT (P = 0.009). 
 
(C) Immunoblotting analysis of whole-cell lysates and 
 
(D) Anti-PTEN immunoprecipitates (IP) derived from HA-ubiquitin (Ub) and Myc-
tagged PTEN transfected HCT116 cells expressing GFP or PARK2 shRNA. Where 
indicated cells were treated with MG132 (10 µM) for 6 hours before collection.  
 
Immunoblotting analysis and anti-PTEN immunoprecipitates derived from  
(E) Myc-tagged WT or C83S mutant PTEN-transfected HCT116 cells expressing 
GFP or PARK2 shRNA. 
 
(F) WT PTEN-transfected shGFP and shPARK2 HCT116 cells, 48 hours post-
transfection with scrambled or AMPK α1 and AMPK α2 siRNAs. 
 
(G) Parental HCT116 treated (or not treated) with the allosteric AMPK activator 991 
for 5 hours (20µM) following 2 hours serum starvation (left), or with 25mM glucose-
containing DMEM (middle) for 6 hours, or with oligomycin (5 µM) for 2 hours. Data 
are represented as mean ±SEM.  
 
See also Figures S5 and S6. 
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Figure 7. In vivo role of Park2 depletion in Pten heterozygous knock-out mice 
(A) Types and frequencies of hamartomas/adenomas/carcinomas/other neoplasms 
found in Pten+/- mice with WT, HET or HOM deletion of Park2. 
 
(B) Frequencies of low- and high-grade prostatic intraepithelial neoplasia (PIN) 
lesions, prostatic low-grade adenocarcinoma and 
 
(C) Different stages of thyroid adenoma/carcinoma lesions found in Pten+/- mice in 
the presence/absence of monoallelic or biallelic Park2 deletion (Prostate lesions: P 
=9.3x10-12, Thyroid lesions: P = 0.002, Chi-squared test). 
 
(D) Representative H&E-stained sections of the low- (left) and high-grade (middle) 
PIN lesions and low-grade adenocarcinoma (right) found in Pten+/- mice with or 
without Park2 deletion. Scale bar is 250-500 µm. 
 
(E) Kaplan–Meier survival plot of Pten+/- mice bearing WT (red) (n=21) or HET (blue) 
(n=27) Park2 deletion (P = 0.0108, Log-rank test). 
 
(F) Kaplan–Meier survival plot of Pten+/- mice bearing WT (red) (n=21) or HOM 
(green) (n=24) Park2 deletion. Both HET and HOM deletion of the Park2 gene 
significantly increased the cancer-related mortality of Pten+/- mice (P = 0.0015, Log-
rank test).  
 
See also Figure S7. 
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Contact for Reagents and Resource Sharing 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, George Poulogiannis (George.Poulogiannis@icr.ac.uk). 
 
 
Experimental Model and Subject Details 
Mice 
Pten+/− heterozygous mice (Di Cristofano et al., 1998) were bred with mice harbouring a 
targeted knockout of Park2 exon 3 (Itier et al., 2003).  All mice were previously backcrossed 
over ten generations and maintained in a C57BL/6 background and they were genotyped by 
PCR for Pten and Park2 alleles as described previously (Di Cristofano et al., 1998; Itier et al., 
2003). Tumor-bearing mice were euthanized and subjected to whole-body histological 
analysis. Normal and tumor tissues were fixed in 4% PFA, embedded in paraffin, sectioned, 
and subjected to hematoxylin and eosin (H&E) staining for pathological evaluation. Survival 
analyses were performed using Kaplan–Meier curves and the Log-rank test. Six- to eight-
week old NOD.CB17-Prkdcscid/J mice were injected via the retrobulbar sinus with 200 µl cell 
suspension (1x106 cells) of GFP flow-sorted luciferase labeled (pLV430G-oFL-T2A-eGFP) 
H1299 cells expressing pLenti6⁄UbC⁄V5-DEST- empty vector or PARK2. Development of 
metastases was monitored by luciferin injection and bioluminescence imaging at 3 and 4 
weeks post-injection. Bioluminescence (BLI) signal intensities were determined by using the 
region of interest (ROI) tool in Living Image® Software (PerkinElmer). After the last imaging 
session the mice were euthanized and the lungs were surgically removed and inflated with 
4% formalin in PBS. Lung sections, 5 µm, were subjected to H&E staining and the number of 
lung tumor nodules was counted using a dissection microscope. All mice were maintained 
according to NIH-approved institutional animal care guidelines and the study was approved 
by the Institutional Committee at the Beth-Israel Deaconess Medical Center.  
 
Cell Culture 
293T and PC3 cells were cultured in DMEM supplemented with 10% fetal bovine serum 
(FBS), 100 U/ml penicillin and 100 µg/ml streptomycin. HCT116 parental and isogenic PTEN 
null cell lines (Lee et al., 2004) were cultured in McCoy’s 5A, H460 and H1299 cells in RPMI, 
and U138 cells in DMEM-F12, all supplemented as above. The breast cancer cell lines MDA-
MB-134, BT-474, UACC-812, MCF-7, Hs-578T, SK-BR-3, AU-565, BT-20 and JIMT-1 were 
cultured in DMEM, and the ZR-75-30 cells in RPMI, all supplemented as above. MCF10A 
parental and isogenic PTEN null cells were cultured in DMEM supplemented with 5% horse 
serum (HS) (ThermoFisher, 16050-122), 20 ng/ml EGF (PeproTech, AF-100-15), 0.5 mg/ml 
hydrocortisone (Sigma-Aldrich, H0888), 100 ng/ml cholera toxin (Sigma-Aldrich, C8052), 10 
µg/ml insulin (Sigma-Aldrich, I1882), supplemented with penicillin and streptomycin as above. 
All cell lines were maintained at 37°C in a humidif ied incubator with 5% CO2 and were tested 
and confirmed to be negative for mycoplasma infection. For glucose starvation experiments, 
cells were washed twice with PBS and then incubated in DMEM without glucose and sodium 
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pyruvate supplemented with 10% dialyzed FBS for 6 hours. For treatment with the allosteric 
AMPK activator 991 (Xiao et al., 2013), cells were serum-starved for 2 hours prior to 991 
treatment for 5 hours. All cell lines used in the study were submitted to Eurofins Genomics for 
autosomal short tandem repeat (STR) authentication.  
 
Method details 
Transfections 
For lentiviral gene knockdown, pLKO.1 shRNA sequences against human PARK2 or GFP 
control were transfected in 293T cells using the FuGENE 6 transfection reagent (Promega, 
E2691) according to the manufacturer's protocols. Infected cells were selected in the 
presence of 2 µg/ml puromycin (InvivoGen, ant-pr-5b) for at least 4 days. Stably expressing 
cancer cell lines were established by infecting with virus encoding human wild-type PARK2, 
the E3 ligase dead C431S mutant or empty vector in the pLenti6⁄UbC⁄V5-DEST backbone 
(ThermoFisher, V49910). Infected cells were selected in the presence of 2-10 µg/ml 
blasticidin (InvivoGen, ant-bl-1) for 2 weeks. For stable expression of luciferase and GFP, 
H1299 cells were infected with pLV430G-oFL-T2A-eGFP (Green et al., 2015), a lentivirus 
expressing the luciferase gene cloned in a eGFP expressing vector (gift from Dr Tina Yuan, 
Dana-Farber Cancer Institute, Harvard Medical School, Boston), and GFP-positive cells were 
sorted by flow cytometry 1 week after infection. H460 cells were transfected with PARK2 
sgRNA CRISPR/Cas9 All-in-One Lentivector Target 3 (Applied Biological Materials, 
K1594608) or control LentiCRISPR v2 according to the manufacturer’s instructions. Infected 
cells were selected in the presence of 2 µg/ml puromycin for 4 days and isolation of PARK2 
clonal deletion mutants was validated by immunoblotting analysis and DNA sequencing. 
 
Immunoblot Analysis 
Cells were washed with ice-cold PBS and lysed on ice for 30 min with cell lysis buffer 
containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
100, supplemented freshly with a protease and phosphatase inhibitor cocktail (5872, Cell 
Signaling Technology), 10nM Calyculin A (Cell Signaling Technology, 9902) and 1 mM DTT 
(ThermoFisher, R0861). Lysates were subjected to centrifugation at 12,000g for 10 min at 
4°C and protein concentrations were determined usin g the Bradford assay (Bio-Rad, 
5000006). Protein lysates were boiled for 10 min and subjected to SDS-PAGE 
electrophoresis. Densitometry was calculated using the Image Lab Software 5.2.1 (Bio-Rad). 
 
Immunohistochemistry 
The GBM tissue microarray (TMA) was prepared and characterized as described previously 
from the Tumor Tissue Bank at University Health Network, University of Toronto (Agnihotri et 
al., 2012). Briefly, the TMA was de-waxed in xylene followed by rehydration in a standard 
alcohol series. Antigen retrieval was by pressure cooking for 20 min in citrate buffer (pH 6.0), 
followed by blocking of endogenous peroxidase in 0.3% H2O2. Antibody incubation was 
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performed using the ABC reagent kit (Vector Labs, PK-6100) as per manufacturers 
instructions. Briefly, Parkin antibody (ThermoFisher, PA1-38412) was diluted 1:100 in 
antibody diluent and added to the slides and incubated overnight at 4oC. Detection was 
performed using biotinylated secondary antibodies for 30 min, the ABC reagent kit and 3,3’-
Diaminobenzidine chromogen. Sections were counter-stained with hematoxylin 
(ThermoFisher, 008001) for 30 secs, dehydrated in 70, 80 and 100% ethanol, briefly washed 
in xylene and mounted in Permount (ThermoFisher, SP-15). For PTEN and phospho-AKT 
immunohistochemistry of mouse tumor sections, antigen retrieval was carried out by 
microwave heating for 20 min in citrate buffer (pH 6.0). Anti-PTEN (Dako, M3627) and anti-
phospho-Akt (Ser473) (Cell Signaling Technology, 4060) antibodies were applied at dilutions 
of 1:200 and 1:50 respectively. PTEN and phospho-Akt IHC staining intensity was graded as 
0 (negative), 1 (weak), 2 (moderate), and 3 (strong). Images were captured on a Nikon E-600 
microscope and analyzed using Nikon ACT-1 software.  
 
PTEN phosphatase activity assay 
For PTEN phosphatase activity assay, PTEN-transfected cells [pRK5-Myc-PTEN-WT, (Song 
et al., 2011)] were lysed in lysis buffer containing protease and phosphatase inhibitors in the 
absence of DTT. PTEN was immunoprecipitated from 1 mg of cell lysates and the PTEN 
phosphatase activity was measured using a PTEN activity ELISA kit (Echelon Biosciences 
Inc, K-4700), following the manufacturer’s instructions. Where indicated, PTEN 
immunoprecipitates were treated with 50 mM DTT at 4oC for 30 min prior to measuring PTEN 
phosphatase activity. 
 
Detection of S-nitrosylated PTEN 
S-nitrosylation of PTEN was detected using the 2,3-diaminonaphthalene (DAN) assay. Briefly, 
PTEN transfected cells (pRK5-Myc-PTEN-WT) were lysed in lysis buffer containing protease 
and phosphatase inhibitors and 40 mM N-ethylmaleimide in the absence of DTT. PTEN was 
immunoprecipitated from equal volume of the diluted cell lysates containing 1 mg of soluble 
protein. The immunoprecipitates were washed twice with lysis buffer and twice with PBS. The 
pellet was resuspended in 500 µl of PBS and 100 µM HgCl2 and 100 µM DAN was added. 
The samples were incubated in the dark at room temperature (RT) for 30 min and 1 M NaOH 
was added. The generated fluorescent triazole from the reaction of DAN with the NO released 
from PTEN was measured using an excitation wavelength of 375 nm and an emission 
wavelength of 450 nm. As a negative control, the PTEN antibody alone in lysis buffer was 
immunoprecipitated and the resulting background fluorescence intensity was subtracted from 
each sample. S-nitrosylated PTEN was confirmed by immunoblotting of immunoprecipitated 
PTEN with anti-S-nitrosocysteine antibody (Abcam, ab94930), under non-reducing conditions. 
For non-reducing SDS-PAGE, β-mercaptoethanol was omitted from the loading buffer and 
samples were not boiled.  
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In cell PTEN ubiquitination assay 
Cellular assays to measure PTEN polyubiquitination were performed as described previously 
(Gupta et al., 2016). Briefly, cells were transfected with vectors encoding wild-type PTEN in 
the pRK5-Myc vector and HA-Ub and lysed in the presence of 40 NEM and supplemented 
freshly with a protease and phosphatase inhibitor cocktail. Equal volume of the diluted cell 
lysates containing 1mg of soluble protein was incubated with 1 µg mouse monoclonal anti-
PTEN (Santa Cruz Biotechnology, sc-7974) or 2 µg mouse anti-HA (BioLegend, 901501) 
antibodies pre-coupled with protein G sepharose beads (Sigma-Aldrich, P3296) and 
incubated at RT for 2 hours rotating. Beads were washed four times in immunoprecipitation 
buffer (50 mmol/L Tris, pH 7.6, 100 mmol/L NaCl, 2 mmol/L EDTA, and 0.2% Nonidet P-40) 
and the bound proteins were released by boiling in SDS-PAGE sample buffer for 10 min, prior 
to SDS-PAGE analysis and immunoblotting with the indicated antibodies.  
 
3H-labeling of phosphoinositides and HPLC analysis 
Subconfluent cells in 10-cm dishes were labeled in 8 ml of inositol-free DMEM and 10% 
dialyzed FBS supplemented with 160 µCi 3H-myo-inositol (PerkinElmer, NET1168001MC, 
specific activity = 20.1 Ci/mmol) for 24 hours. Deacylated phosphoinositides were resolved by 
HPLC using an Agilent 1200 Quaternary system, and radioactivity detected in-line using a 
Packard Flo-one Radiomatic detector. HPLC Buffer A is 1 mM EDTA, and Buffer B is 1 mM 
EDTA and 1 M NaH2PO4. An Agilent Zorbax SAX column (5 µm, 4.6 X 250 mm) was eluted 
by gradient program (from 100% A to 2% B at 1 min, 14% B at 30 min, 30% B at 31 min, 66% 
at 60 min, 100% B at 85 min, 100% A at 86 min, and hold at 100% A until 110 min) at a flow 
rate of 1 ml/min. PI(3,4)P2, PI(3,4,5)P3 standards were prepared by reacting PI3K with PI4P 
and PI5P, respectively and [γ-32P]ATP.   
 
MTS and caspase-3/7 assays 
Cell viability was assessed using the CellTiter96® AQueous non-radioactive cell proliferation 
assay [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] (Promega, G5421) according to the manufacturer’s protocol.  
Caspase-3/7 activities were measured using the Caspase-Glo® 3/7 assay (Promega, G8090) 
following treatment with 50 or 100 nM staurosporine (Sigma-Aldrich, S4400) for 1 hour. For 
both cell viability and caspase 3/7 assays, HCT116 cells were seeded at 3x104 cells/well in a 
96-well plate and incubated overnight before treatment. 
 
Cell proliferation and cell migration assays 
Proliferation kinetics of H1299, PC3, HCT116 PTEN+/+ and HCT116 PTEN−/− cells transfected 
with pLenti6/UbC/V5-DEST-PARK2-WT, PARK2-C431S mutant or empty vector were 
determined using the Sulforhodamine B (SRB) (Sigma-Aldrich, S1402) assay over a period of 
5 days. The same method was applied for shGFP and shPARK2-expressing PC3 cells 
transfected with pHR-SIN-PTEN-WT, PTEN-C83S and control empty vector. Briefly, 2x103 
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cells were seeded in a 96-well plate in triplicate and allowed to adhere for 24 hours (Day 0). 
Cells were fixed at days 0, 1, 3 and 5 as follows: they were fixed with 10% trichloracetic acid 
at 4°C for 60 min and washed 4x with 100 µl dH2O. After being left to dry at RT, the cells were 
stained for 10 min with 0.4% (w/v) SRB dissolved in 1% acetic acid, and protein-bound dye 
was extracted with 10 mM unbuffered Tris base pH 10.5. Absorbance was determined at 510 
nm using a 96-well microplate reader and data presented indicate the average number of 
triplicate experiments ± standard error of the mean (SEM). 
For cell migration assays, cells were starved overnight in 0.5% FBS and 5x104 cells/well were 
seeded in 24-well transwell chambers (Corning, Lowell, MA, USA; 8 mm pore size) in a total 
volume of 300 µl 0.5% FBS-media. 750 µl of media (supplemented with 10%FBS) were 
added to the bottom of the transwells and the plates were returned to 37°C for 24-hour 
incubation. The transwell inserts were washed twice in PBS and cells were fixed in 10% 
trichloroacetic acid (TCA) for 1 hour. The TCA containing media was removed and the inserts 
were washed 3x in H2O. Cells were stained in 0.4% (w/v) SRB dissolved in 1% acetic acid for 
10 min. The inserts were washed 3x in 1% acetic acid and the cells on the top of the filter 
were removed using a cotton swab. Migrated SRB-stained cells in the bottom of the transwell 
inserts were counted under a light microscope at 20x magnification in 5 fields/well.  
 
Cytotoxicity and clonogenic assays 
For determination of the IC50 values of 2-DG and DCA, shGFP- or shPARK2-expressing PC3 
cells were co-transfected with pHR-SIN-PTEN-WT, PTEN-C83S and control empty vector. 48 
hours post transfection, the cells were seeded at 5x103 cells/well in a 96-well plate and 
treated with various concentrations of 2-DG (0.5-50 mM) or DCA (5-80 mM) for 72 hours 
followed by SRB staining. For clonogenic assays, cells were plated at 1×102 cells/well in 24-
well plates and treated with 10 mM DCA or 0.5 mM 2-DG. After 10 days, colonies were 
stained with a Crystal Violet solution (0.5% Crystal Violet, Sigma, 30% ethanol and 3% 
formaldehyde) and were counted in a GelCountTM (Oxford Optronix). Every experiment was 
performed in triplicate and data are presented as mean values ±SEM. 
 
Real-Time qRT-PCR 
Total RNA was extracted using the ReliaPrep RNA cell miniprep system (Promega, Z6010) 
according to the manufacturer’s instructions. Reverse transcription and real-time PCR 
reactions were carried out using the QuantiTect reverse transcription kit (Qiagen, 205310) 
and SYBR select master mix (ThermoFisher, 4472908) respectively, using the TProfessional 
ThermoCycler from Biometra. The data presented are the mean values obtained ±SEM from 
triplicate reactions. Primer sequences used are as follows; Human PARK2, sense: 
TCAATCTACAACAGCTTTTATG, anti-sense: TGCACTAGTCCCAGGGCA (Hedrich et al., 
2001), Human PTEN, sense: CAAGATGATGTTTGAAACTATTCCAATG, anti-sense: 
CCTTTAGCTGGCAGACCACAA (Kim et al., 2004), Human 18S, sense: 
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GTGGAGCGATTTGTCTGGTT, anti-sense: CGCTGAGCCAGTCAGTGTAG (Leonard et al., 
2003). 
 
ROS, NO, GSH/GSSG and NOS activity measurements 
H2O2 levels were measured using the ROS-Glo™ H2O2 assay (Promega, G8820) according 
to the manufacturer's instructions. Briefly, 1x104 shGFP control and shPARK2-expressing 
cells were seeded in a 96-well plate and incubated at 37°C and 5% CO2 for 18 hours. Cells 
were washed with PBS and treated in Hank’s BSS medium containing 20 µM menadione 
(Sigma-Aldrich, M5625) in the presence of 20 µl 125 µM H2O2 substrate (provided in the kit). 
Following incubation at 37oC for 2 hours, 100 µl of ROS-Glo detection solution was added to 
the wells and the plate was incubated for 20 min at RT. Luminescence was determined with a 
microplate reader and the average relative light units (RLU) ±SEM of triplicate data are 
reported.  
Nitric oxide (NO) levels were detected using the Nitric Oxide Assay Kit (abcam, ab65327) 
according to the manufacturer’s protocol. Briefly, shGFP and shPARK2-expressing cells were 
grown in regular culture medium for 24 hours. After washing with cold PBS, 2x106 cells were 
resuspended in 500 µl assay buffer and homogenised quickly by pipetting up and down a few 
times. The samples were centrifuged for 5 min at 4oC at top speed to remove any insoluble 
material. Triplicate 75 µl aliquots of the supernatant were transferred to a 96-well plate and 5 
µl of enzyme cofactor and 5 µl of nitrate reductase were added to each of the reaction wells. 
The plate was incubated at RT for 3 hours and 5 µl of enhancer was added to each well, 
before further incubation for 30 min at RT. 5 µl of the DAN probe was added to each well, the 
plate was incubated at RT for 10 min and 5 µl of NaOH was added before final incubation at 
RT for 10 min. Fluorescence was determined with a microplate reader at Ex/Em = 
360/450nm. All reagents were provided in the kit. GSH:GSSG levels were measured using 
the GSH/GSSG-Glo™ Assay kit (Promega, V6611) and nitric oxide synthase (NOS) activity 
was determined using the NOS activity assay kit (BioVision, K205-100) according to the 
manufacturer’s protocol. 
 
Mitochondrial flux analysis 
PARK2 and GFP stable knockdown cells were plated at 2x104/well in a 96-well Seahorse cell 
culture microplate and incubated overnight. The next morning, culture media was replaced 
with pH-adjusted (pH=7.4±0.1) bicarbonate-free DMEM with 10 mM Glucose, 1 mM sodium 
pyruvate and 2 mM L-Glutamine and the plate was incubated at 37°C for 1 hour in a non–
CO2 incubator. Oxygen consumption rates were measured using the Seahorse XF Cell Mito 
Stress Kit (Agilent, 103015-100) on a XFe96 Analyzer. 2 µM Oligomycin, 0.5 µM FCCP, and 
0.5 µM rotenone/antimycin (R/A) were used for all conditions. Cell numbers were normalised 
using Cyquant (ThermoFisher, C35012). 
 
Tandem Mass Spectrometry 
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Metabolite levels were determined by targeted liquid-chromatography tandem mass 
spectrometry (LC-MS/MS) analysis as described previously (Yuan et al., 2012). Briefly, 48 
hours prior to each experiment, 2.5x105 HCT116 cells expressing shGFP or shPARK2 were 
seeded in 6-cm dishes. The media for each plate was replaced 2 hours prior to metabolite 
extraction and after aspiration, 4 mL pre-chilled (at -80 °C) methanol was added to the cells 
on dry ice for 15 min. Cell extracts were collected into 15 mL conical tubes and centrifuged for 
5 min at 4200 rpm. Solvent in the resulting supernatant was evaporated using a centrifugal 
vacuum evaporator (“SpeedVac”) and samples were re-suspended in 20 µL HPLC-grade 
water for mass spectrometry. 8 µL were injected and analyzed using a Prominence UFLC 
HPLC system (Shimadzu) for hydrophilic interaction liquid chromatography (HILIC), coupled 
to a QTRAP 5500 hybrid triple quadrupole/linear ion trap mass spectrometer (SCIEX) 
operated in the selected reaction monitoring (SRM) mode. Peak areas of LC-SRM-MS traces 
for each metabolite were integrated using the MultiQuant v1.1 software (SCIEX). 
 
Quantification and Statistical Analysis 
Bioinformatic Analysis 
GISTIC (Genomic Identification of Significant Targets in Cancer) analyses were performed on 
DNA copy number data from the SNP pipeline version 3.0. 9,863 tumor samples across 28 
cancer types were selected for this analysis using the 2015-06-01 stddata TCGA/GDAC 
tumor sample sets from FireHose, and the frequencies of PARK2 DNA copy number changes 
were plotted using a polar histogram. The Oncomine cancer profiling database was used to 
analyze PARK2 mRNA expression across 13,499 cancerous and 2,708 normal tissue 
specimens from 125 independent microarray datasets representing 27 different cancer types. 
The degree of PARK2 mRNA underexpression (≥0.5 and ≥1-log2-fold change in tumor versus 
normal) was plotted across all tumor types. Kaplan-meier analysis in Figure S1C was 
performed using the KM plotter (Szasz et al., 2016). Student t-test and one- or two-way 
Anova were used to evaluate the statistical significance among different variables as 
indicated in the respective figure legends, P: n.s. (not significant), * (P < 0.05), ** (P < 0.01). 
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